AVEO garners $100M from stock offering

AVEO Pharmaceuticals says it will net slightly more than $100 million on its sale of 5.75 million discounted shares, much of which will be used for its ambitious R&D plans. The developer recently grabbed an impressive $125 million upfront from its partnership with Astellas on tivozanib, a promising experimental cancer drug. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.